Literature DB >> 10426887

The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life.

L A Drake1, D L Patrick, P Fleckman, J Andr, R Baran, E Haneke, C Sapède, A Tosti.   

Abstract

BACKGROUND: Onychomycosis is a widespread refractory disease deleteriously affecting quality of life via social stigma and disrupting daily activities. Many physicians perceive onychomycosis as a cosmetic rather than a medical problem.
OBJECTIVE: Our purpose was to develop a questionnaire-based instrument to quantify the impact of onychomycosis on patients' quality of life.
METHODS: The questionnaire was developed and validated in a multinational cross-sectional study. Completed questionnaires from 532 patients were analyzed: 284 toenail, 248 fingernail (onychomycosis or paronychia).
RESULTS: The degree of quality of life impairment from onychomycosis varied by country studied, possibly reflecting cross-national health perception differences. Longer duration of disease, greater involvement of individual nails, and greater number of nails involved were associated with more serious adverse effects. Many physicians underestimated the associated degree of pain.
CONCLUSION: The study confirms that onychomycosis physically and psychologically affects patients' lives. The questionnaire may be a valuable tool in evaluating the effect of therapeutic agents on quality of life of patients with onychomycosis.

Entities:  

Mesh:

Year:  1999        PMID: 10426887     DOI: 10.1016/s0190-9622(99)70047-2

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  29 in total

Review 1.  Oral antifungal medication for toenail onychomycosis.

Authors:  Sanne Kreijkamp-Kaspers; Kate Hawke; Linda Guo; George Kerin; Sally Em Bell-Syer; Parker Magin; Sophie V Bell-Syer; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-07-14

Review 2.  Natural Products: An Alternative to Conventional Therapy for Dermatophytosis?

Authors:  Graciliana Lopes; Eugénia Pinto; Lígia Salgueiro
Journal:  Mycopathologia       Date:  2016-10-22       Impact factor: 2.574

Review 3.  Which antifungal agent for onychomycosis? A pharmacoeconomic analysis.

Authors:  V N Joish; E P Armstrong
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  Patient-Reported Outcomes in Onychomycosis: A Review of Psychometrically Evaluated Instruments in Assessing Treatment Effectiveness.

Authors:  Jenny Wang; Lauren E Wiznia; Evan A Rieder
Journal:  Skin Appendage Disord       Date:  2017-04-21

5.  Toenail onychomycosis in a Portuguese geriatric population.

Authors:  N Dias; C Santos; M Portela; N Lima
Journal:  Mycopathologia       Date:  2011-03-02       Impact factor: 2.574

Review 6.  Onychomycosis: health-related quality of life considerations.

Authors:  James W Shaw; Vijay N Joish; Stephen Joel Coons
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

7.  Treatment of onychomycosis with efinaconazole 10% topical solution and quality of life.

Authors:  Antonella Tosti; Bom E Elewski
Journal:  J Clin Aesthet Dermatol       Date:  2014-11

8.  Increase in resistance to fluconazole and itraconazole in Trichophyton rubrum clinical isolates by sequential passages in vitro under drug pressure.

Authors:  Anita Hryncewicz-Gwóźdź; Katarzyna Kalinowska; Ewa Plomer-Niezgoda; Jacek Bielecki; Tomasz Jagielski
Journal:  Mycopathologia       Date:  2013-04-18       Impact factor: 2.574

Review 9.  The role of topical antifungal therapy for onychomycosis and the emergence of newer agents.

Authors:  James Q Del Rosso
Journal:  J Clin Aesthet Dermatol       Date:  2014-07

10.  Efinaconazole 10% solution: a new topical treatment for onychomycosis: contact sensitization and skin irritation potential.

Authors:  James Q Del Rosso; Barry Reece; Kathleen Smith; Terri Miller
Journal:  J Clin Aesthet Dermatol       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.